Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study

This article was originally published in The Tan Sheet

Executive Summary

Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.

Advertisement

Related Content

Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana
Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana
GAO Backs Prescription Pseudoephedrine Approach
Electronic Tracking Success Could End Rx-Only Pseudoephedrine In Mississippi
Tennessee Emerges As PSE Battleground With Rx, NPLEx Proposals
Rx-Only Pseudoephedrine Legislation Spreads To More States

Topics

Advertisement
UsernamePublicRestriction

Register

PS106277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel